Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/143373
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease

AutorSogorb-Esteve, Aitana CSIC; García-Ayllón, María-Salud CSIC ORCID; Fortea, Juan; Sánchez-Valle, Raquel; Lleó, Alberto; Molinuevo, José Luis; Sáez-Valero, Javier CSIC ORCID
Palabras clavePresenilin-1
Cerebrospinal fluid
Biomarkers
Pre-symptomatic
Autosomal dominant
Alzheimer’s disease
Down syndrome
Mild-cognitive impairment
Fecha de publicación29-sep-2016
EditorEdufma
CitaciónMolecular Neurodegeneration 11: 66 (2016)
Resumen[Background] Presenilin-1 (PS1), the active component of the intramembrane γ-secretase complex, can be detected as soluble heteromeric aggregates in cerebrospinal fluid (CSF). The aim of this study was to examine the different soluble PS1 complexes in the lumbar CSF (CSF-PS1) of individuals with Alzheimer’s disease (AD), particularly in both symptomatic and asymptomatic genetically determined AD, in order to evaluate their potential as early biomarkers.
[Methods] Western blotting, differential centrifugation and co-immunoprecipitation served to determine and characterize CSF-PS1 complexes. We also monitored the assembly of soluble PS1 into complexes in a cell model, and the participation of Aβ in the dynamics and robustness of the stable PS1 complexes.
[Results] There was an age-dependent increase in CSF-PS1 levels in cognitively normal controls, the different complexes represented in similar proportions. The total levels of CSF-PS1, and in particular the proportion of the stable 100–150 kDa complexes, increased in subjects with autosomal dominant AD that carried PSEN1 mutations (eight symptomatic and six asymptomatic ADAD) and in Down syndrome individuals (ten demented and ten non-demented DS), compared with age-matched controls (n = 23), even prior to the appearance of symptoms of dementia. The proportion of stable CSF-PS1 complexes also increased in sporadic AD (n = 13) and mild-cognitive impaired subjects (n = 12), relative to age-matched controls (n = 17). Co-immunoprecipitation demonstrated the association of Aβ oligomers with soluble PS1 complexes, particularly the stable complexes.
[Conclusions] Our data suggest that CSF-PS1 complexes may be useful as an early biomarker for AD, reflecting the pathology at asymptomatic state.
Versión del editorhttps://doi.org/10.1186/s13024-016-0131-2
URIhttp://hdl.handle.net/10261/143373
DOI10.1186/s13024-016-0131-2
ISSN1750-1326
Aparece en las colecciones: (IN) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
cerebrospinal_fluid_Sogord.pdf1,85 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

5
checked on 17-mar-2024

SCOPUSTM   
Citations

7
checked on 12-mar-2024

WEB OF SCIENCETM
Citations

8
checked on 28-feb-2024

Page view(s)

278
checked on 18-mar-2024

Download(s)

204
checked on 18-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.